Methapyrilene (MP) exposure of animals can result in an array of adverse pathological responses including hepatotoxicity. This study investigates gene expression and histopathological alterations in response to MP treatment in order to 1) utilize computational approaches to classify samples derived from livers of MP treated rats based on severity of toxicity incurred in the corresponding tissue, 2) to phenotypically anchor gene expression patterns, and 3) to gain insight into mechanism(s) of methapyrilene hepatotoxicity. Large-scale differential gene expression levels associated with the exposure of male Sprague—Dawley rats to the rodent hepatic carcinogen MP for 1, 3, or 7 days after daily dosage with 10 or 100 mg/kg/day were monitored. Hierarchical clustering and principal component analysis were successful in classifying samples in agreement with microscopic observations and revealed low-dose effects that were not observed histopathologically. Data from cDNA microarray analysis corroborated observed histopathological alterations such as hepatocellular necrosis, bile duct hyperplasia, microvesicular vacuolization, and portal inflammation observed in the livers of MP exposed rats and provided insight into the role of specific genes in the studied toxicological processes.
Abdo KM, Cunningham ML, Snell ML, Herbert RA, Travlos GS, Eldridge SR, Bucher JR (2001). 14-Week toxicity and cell proliferation of methyleugenol administered by gavage to F344 rats and B6C3F1 mice. Food Chem Toxicol39: 303—316.
2.
Ammendola R. , Fiore F., Esposito F., Caserta G., Mesuraca M., Russo T., Cimino F. (1995). Differentially expressed mRNAs as a consequence of oxidative stress in intact cells. FEBS Lett371: 209—213.
3.
Brennan LM, Creasia DA (1982). The effects of methapyrilene hydrochloride on hepatocarcinogenicity and pentobarbital-induced sleeping time in rats and mice. Toxicol Appl Pharmacol66: 252—258.
4.
Budroe JD, Shaddock JG, Casciano DA (1984). A study of the potential genotoxicity of methapyrilene and related antihistamines using the hepatocyte/DNA repair assay. Mutat Res135: 131—137.
5.
Bushel PR, Hamadeh H., Bennett L., Sieber S., Martin K., Nuwaysir EF, Johnson K., Reynolds K., Paules RS, Afshari CA (2001). MAPS: A microarray project system for gene expression experiment information and data validation. Bioinformatics17: 564—565.
6.
Calandre EP, Alferez N., Hassanein K., Azarnoff DL (1981). Methapyrilene kinetics and dynamics. Clin Pharmacol Ther29: 527—532.
7.
Casciano DA, Schol HM (1984). Methapyrilene is inactive in the hepatocyte-mediated Chinese hamster ovary/hypoxanthine-guanine phosphoribosyl transferase mutational assay. Cancer Lett21: 337—341.
8.
Casciano DA, ShaddockJG, TalaskaG.( 1988). The potent hepatocarcinogen methapyrilene does not form DNA adducts in livers of Fischer 344 rats. Mutat Res208: 129—135.
9.
Casciano DA, Talaska G., Clive D. (1991). The potent hepatocarcinogen methapyrilene induces mutations in L5178Y mouse lymphoma cells in the apparent absence of DNA adduct formation. Mutat Res263: 127—132.
10.
Chassin D., Benifla JL, Delattre C., Fernandez H., Ginisty D., Janneau JL, Prade M., Contesso G., Caillou B., Tournaire M. (1994). Identification of genes overexpressed in tumors through preferential expression screening in trophoblasts. Cancer Res54: 5217—5223.
11.
Chen Y., Dougherty ER, Bittner ML (1997). Ratio-based decisions and the quantitative analysis of cDNA microarray images. J Biomed Optics2: 364— 374.
12.
Comolli R., Alberti P., Giribaldi G. (1989). Activation of a ribosomal S6 protein kinase in rapidly emerging diethylnitrosamine-induced gammaglutamyltranspeptidase-positive hyperplastic liver lesions of the rat. Tumori75: 527—532.
13.
Copple DM, Rush GF, Richardson FC (1992). Effects of methapyrilene measured in mitochondria isolated from naive and methapyrilene-treated rat and mouse hepatocytes. Toxicol Appl Pharmacol116: 10—16.
14.
Cunningham ML, Pippin LL, Anderson NL, Wenk ML (1995). The hepatocarcinogen methapyrilene but not the analog pyrilamine induces sustained hepatocellular replication and protein alterations in F344 rats in a 13-week feed study. Toxicol Appl Pharmacol131: 216—223.
15.
Cunningham ML (1996). Role of increased DNA replication in the carcinogenic risk of nonmutagenic chemical carcinogens . Mutat Res365: 59—69.
16.
Cunningham ML (2000). Cell proliferation as a determining factor for the carcinogenicity of chemicals. In: Molecular Drug Metabolism and Toxicology, Williams GM, Aruoma OI (eds). OICA International Press, London, pp 82—94.
17.
Duggan DJ, Bittner M., Chen Y., Meltzer P., Trent JM (1999). Expression profiling using cDNA microarrays. Nat Genet21: 10—14.
18.
Eisen MB, Spellman PT, Brown PO, Botstein D. (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA95: 14863—14868.
Habs M., Shubik P., Eisenbrand G. (1986). Carcinogenicity of methapyrilene hydrochloride, mepyramine hydrochloride, thenyldiamine hydrochloride, and pyribenzamine hydrochloride in Sprague—Dawley rats. J Cancer Res Clin Oncol111: 71—74.
21.
Hamadeh HK, Bushel PB, Jayadev S., Martin K., DiSorbo O., Sieber S., Bennett L., Tennant R., Stoll R., Barrett JC, Blanchard K., Paules RS, Afshari CA (in press). Gene expression analysis reveals chemical-specific profiles . Toxicol Sci67: 219—231.
22.
Hamadeh HK, Bushel P., Martin K., Bennett L., Paules R., Afshari CA (2002). Detection of diluted gene expression alterations using cDNA microarrays. BioTechniques32: 322—329.
23.
Holtta E., Janne J. (1972). Ornithine decarboxylase activity and the accumulation of putrescine at early stages of liver regeneration. FEBS Lett23: 117—121.
24.
Iype PT, Ray-Chaudhuri R., Lijinsky W., Kelley SP (1982). Inability of methapyrilene to induce sister chromatid exchanges in vitro and in vivo. Cancer Res42: 4614—4618.
25.
Johnson JD, Ryan MJ, Toft JDII, Graves SW, Hejtmancik MR, Cunningham ML, Herbert R., Abdo KM ( 2000). Two-year toxicity and carcinogenicity study of methyleugenol in F344/N rats and B6C3F(1) mice. J Agric Food Chem48: 3620—3632.
26.
Jolliffe IT (1986). Principal Component Analysis. Springer Verlag, New York.
27.
Kammerer RC , Schmitz DA (1987). Species differences in the in vitro metabolism of methapyrilene. Xenobiotica17: 1121—1130.
28.
Kondoh N., Noda M., Fisher RJ, Schweinfest CW, Papas TS, Kondoh A., Samuel, KP, Oikawa T. (1996). The S29 ribosomal protein increases tumor suppressor activity of K rev- 1 gene on v-K ras-transformed NIH3T3 cells. Biochim Biophys Acta1313: 41—46.
29.
Lampe MA, Kammerer RC (1990). Species differences in the metabolism and macromolecular binding of methapyrilene: A comparison of rat, mouse and hamster. Xenobiotica20: 1269—1280.
30.
Levy E., Rizwan Y., Thibault L., Lepage G., Brunet S., Bouthillier L., Seidman E. (2000). Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr71: 807—815.
31.
Lijinsky W. , Reuber MD, Blackwell BN (1980). Liver tumors induced in rats by oral administration of the antihistaminic methapyrilene hydrochloride . Science209: 817—819.
32.
Lijinsky W. , Knutsen G., Reuber MD (1983). Failure of methapyrilene to induce tumors in hamsters or guinea pigs. J Toxicol Environ Health12: 653—657.
33.
Lijinsky W. (1984). Chronic toxicity tests of pyrilamine maleate and methapyrilene hydrochloride in F344 rats. Food Chem Toxicol22: 27—30.
34.
Lijinsky W. , Yamashita K. (1988). Lack of binding of methapyrilene and similar antihistamines to rat liver DNA examined by 32P postlabeling. Cancer Res48: 6475—6477.
35.
Lusis AJ, Heinzmann C., Sparkes RS, Scott J., Knott TJ, Geller R., Sparkes MC, Mohandas T. (1986). Regional mapping of human chromosome 19: Organization of genes for plasma lipid transport (APOC1, -C2, and -E and LDLR) and the genes C3, PEPD, and GPI. Proc Natl Acad Sci USA83: 3929—3933.
36.
Mirsalis JC (1987). Genotoxicity, toxicity, and carcinogenicity of the antihistamine methapyrilene. Mutat Res185: 309—317.
37.
Mizuta K., Hashimoto E., Sakanoue Y., Nakamura S., Kondo H., Yamamura H. (1987). An activated S6 kinase in regenerating rat liver . Biochem Biophys Res Commun146: 239—246.
38.
Oberly TJ, Scheuring JC, Richardson KA, Richardson FC, Garriott ML (1993). The evaluation of methapyrilene for bacterial mutation with metabolic activation by Aroclor-induced, methapyrilene-induced and noninduced rat-liver S9. Mutat Res299: 77—84.
39.
Parola M., Bellomo G., Robino G., Barrera G., Dianzani MU (1999). 4-Hydroxynonenal as a biological signal: Molecular basis and pathophysiological implications. Antioxid Redox Signal1: 255—284.
40.
Pogue-Geile K. , Geiser JR, Shu M., Miller C., Wool IG, Meisler AI, Pipas JM (1991). Ribosomal protein genes are overexpressed in colorectal cancer: Isolation of a cDNA clone encoding the human S3 ribosomal protein. Mol Cell Biol11: 3842—3849.
41.
Preston-Martin S., Pike MC, Ross RK, Jones PA, Henderson BE (1990). Increased cell division as a cause of human cancer. Cancer Res50: 7415— 7421.
42.
Raina A., Janne J. (1968). Biosynthesis of putrescine: Characterization of ornithine decarboxylase from regenerating rat liver. Acta Chem Scand22: 2375—2378.
43.
Ratra GS, Cottrell S., Powell CJ (1998). Effects of induction and inhibition of cytochromes P450 on the hepatotoxicity of methapyrilene. Toxicol Sci46: 185—196.
44.
Ratra GS, Morgan, WA, Mullervy J., Powell CJ, Wright MC (1998). Methapyrilene hepatotoxicity is associated with oxidative stress, mitochondrial disfunction and is prevented by the Ca2+ channel blocker verapamil. Toxicology130: 79—93.
45.
Ratra GS, Powell CJ, Park BK, Maggs JL, Cottrell S. (2000). Methapyrilene hepatotoxicity is associated with increased hepatic glutathione, the formation of glucuronide conjugates, and enterohepatic recirculation. Chem Biol Interact129: 279—295.
46.
Ray G., Husain SA (2001). Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem34: 71—76.
47.
Reznik-Schuller HM, Lijinsky W. (1982). Ultrastructural changes in the liver of animals treated with methapyrilene and some analogs . Ecotoxicol Environ Saf6: 328—335.
48.
Reznik-Schuller HM, Reuber MD (1986). Ultrastructure of liver tumors induced in F344 rats by methapyrilene. J Environ Pathol Toxicol Oncol7: 181—195.
49.
Richardson FC, Copple DM, Eacho PI (1992). Effects of methapyrilene on DNA synthesis in mice and rats following continuous dietary exposure. Carcinogenesis13: 2453—2457.
50.
Richardson FC, Horn DM, Anderson NL (1994). Dose-responses in rat hepatic protein modification and expression following exposure to the rat hepatocarcinogen methapyrilene. Carcinogenesis15: 325— 329.
51.
Richter C., Frei B. ( 1988). Ca2+ release from mitochondria induced by prooxidants . Free Radic Biol Med4: 365—375.
52.
Sasaki Y., Itoh F., Suzuki H., Kobayashi T., Kakiuchi H., Hareyama M., Imai K. ( 2000). Identification of genes highly expressed in G2-arrested Chinese hamster ovary cells by differential display analysis. J Clin Lab Anal14: 314—319.
53.
Singer SS, Lijinsky W., Kratz LE, Castagnoli N.Jr, Rose JE ( 1987). A comparison of in vivo and in vitro metabolites of the H1-antagonist N,N-dimethyl-N'-2-pyridyl-N'-(2-thienylmethyl)-1,2-ethanediamine (methapyrilene) in the rat. Xenobiotica17: 1279—1291.
54.
Steinmetz KL , Tyson CK, Meierhenry EF, Spalding JW, Mirsalis JC (1988). Examination of genotoxicity, toxicity and morphologic alterations in hepatocytes following in vivo or in vitro exposure to methapyrilene. Carcinogenesis9: 959—963.
55.
Uwabe K., GaharaY., YamadaH., Miyake T., KitamuraT.( 1997). Identification and characterization of a novel gene (neurorep 1) expressed in nerve cells and up-regulated after axotomy. Neuroscience80: 501—509.
56.
Volarevic S. , Stewart MJ, Ledermann B., Zilberman F., Terracciano L., Montini E., Grompe M., Kozma SC, Thomas G. (2000). Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science288: 2045—2047.
57.
Wang Q., Yang C., Zhou J., Wang X., Wu M., Liu Z. (2001). Cloning and characterization of full-length human ribosomal protein L15 cDNA which was overexpressed in esophageal cancer. Gene263: 205—209.
58.
Waring JF, Ciurlionis R., Jolly RA, Heindel M., Ulrich RG (2001). Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity . Toxicol Lett120: 359—368.
59.
Waring JF, Jolly RA, Ciurlionis R., Lum PY, Praestgaard JT, Morfitt DC, Buratto B., Roberts C., Schadt E., Ulrich RG (2001). Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol Appl Pharmacol175: 28—42.
60.
Weis M., Kass GE, Orrenius S. (1994). Further characterization of the events involved in mitochondrial Ca2+ release and pore formation by prooxidants. Biochem Pharmacol47: 2147—2156.
61.
Wrighton SA , VandenBranden M., Brown TJ, Van Pelt CS, Thomas PE, Shipley LA (1991). Modulation of rat hepatic cytochromes P450 by chronic methapyrilene treatment . Biochem Pharmacol42: 1093—1097.
62.
Xu W., Wang S., Wang G., Wei H., He F., Yang X. ( 2000). Identification and characterization of differentially expressed genes in the early response phase during liver regeneration. Biochem Biophys Res Commun278: 318— 325.
